Screener / SEC EDGAR /CIK 0001819790 /10-K filed Feb 23, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Tarsus Pharmaceuticals, Inc. TARS

Compare with peers Embed
Planned sales, announced before they happen

6 trading plans running, 48 Form 144 notices for $36.8M

10-Q, 10-K and Form 144
Plans running now 6 Andrew Goldberg, Elizabeth Yeu-Lin, spouse of Ms. Yeu-Lin, Katherine Goodrich, Dr. Azamian, William Link
Plans adopted 10 reported since May 9, 2023 Form 144 notices 48 $36.8M the sellers expected to sell

What TARS's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From Nov 13, 2025 to Sep 10, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired.

InsiderWhatDateReported in
Andrew Goldberg
Board of Directors
Adopted 10b5-1 plan Sep 11, 2026 10-Q Nov 3, 2026
What the company wrote
On September 11, 2026, Andrew Goldberg, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement (the “Goldberg Plan”) intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The Goldberg Plan provides for the potential sale of up to 13,700 shares of common stock held by Mr. Goldberg between December 11, 2026 and January 4, 2027. The Goldberg Plan also provides for the sale of up to 20,000 shares of common stock that will be acquired through the cashless exercise of non-qualified stock options, between December 11, 2026 and September 10, 2027.
Elizabeth Yeu-Lin
Chief Medical Officer
Adopted 10b5-1 plan Jun 1, 2026 10-Q Aug 6, 2026
What the company wrote
On June 1, 2026, Elizabeth Yeu-Lin, our Chief Medical Officer, adopted a Rule 10b5-1 trading arrangement (the “Yeu-Lin Plan”) intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The Yeu-Lin Plan provides for the potential sale of up to 9,506 shares of common stock held by Ms. Yeu-Lin between September 1, 2026 and August 31, 2027.
spouse of Ms. Yeu-Lin
Adopted 10b5-1 plan Jun 1, 2026 10-Q Aug 6, 2026
What the company wrote
Also on June 1, 2026, the spouse of Ms. Yeu-Lin adopted a Rule 10b5-1 trading arrangement (the “Spousal Plan”) covering shares of the Company's common stock in which Ms. Yeu-Lin has an indirect pecuniary interest reportable under Section 16 of the Exchange Act. The Spousal Plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) and provides for the potential sale of up to 6,360 shares of the Company's common stock, between September 1, 2026 and September 1, 2027.
Katherine Goodrich
Board of Directors
Adopted 10b5-1 plan Mar 2, 2026 10-Q May 6, 2026
What the company wrote
On March 2, 2026, Katherine Goodrich, a member of our Board of Directors, adopted a Rule 10b5-1 trading plan to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provides for the sale of up to 5,187 shares of common stock held by Ms. Goodrich between June 12, 2026 and June 2, 2027.
Seshadri Neervannan
Chief Operating Officer
Adopted 10b5-1 plan Nov 13, 2025 10-K Feb 23, 2026
What the company wrote
In December 2025, Dr. Azamian, adopted a new Rule 10b5-1 trading plan. The plan provides for the sale of up to 60,000 shares of common stock held by Dr. Azamian between March 24, 2026 and March 24, 2027. On November 13, 2025, Seshadri Neervannan, our Chief Operating Officer, adopted a Rule 10b5-1 trading plan to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provides for the sale of up to 18,027 shares of common stock held by Dr. Neervannan between March 4, 2026 and March 16, 2026.
Jose Trevejo
former Chief Medical Officer
Ended 10b5-1 plan Jan 12, 2024 10-Q May 8, 2024
What the company wrote
In May 2023, Jose Trevejo, former Chief Medical Officer, adopted a Rule 10b5-1 trading plan to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provided for the sale of up to 6,107 shares of common stock held by Dr. Trevejo between August 17, 2023 and May 16, 2024. Dr. Trevejo terminated the trading plan effective January 12, 2024.
Bobak Azamian
Chief Executive Officer
Ended 10b5-1 plan Jan 8, 2024 10-Q May 8, 2024
What the company wrote
In May 2023, Bobak Azamian, Chief Executive Officer, adopted a Rule 10b5-1 trading plan to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provided for the sale of up to 291,000 shares of common stock held by Dr. Azamian between August 23, 2023 and July 24, 2024. Dr. Azamian terminated the trading plan effective January 8, 2024.
Aziz Mottiwala
Chief Commercial Officer
Adopted 10b5-1 plan – 10-Q May 1, 2025
What the company wrote
In March 2025, Aziz Mottiwala, our Chief Commercial Officer, adopted a Rule 10b5-1 trading plan to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provides for the sale of up to 17,500 shares of common stock held by Mr. Mottiwala between June 9, 2025 and June 9, 2026.
Bobak Azamian
Chief Executive Officer
Adopted 10b5-1 plan – 10-K Feb 25, 2025
What the company wrote
In December 2024, Bobak Azamian, our Chief Executive Officer, adopted a Rule 10b5-1 trading plan to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provides for the sale of up to 24,000 shares of common stock held by Dr. Azamian between March 24, 2025, and March 23, 2026.
Dianne Whitfield
Chief Human Resources Officer
Adopted 10b5-1 plan – 10-Q Nov 4, 2025
What the company wrote
In September 2025, Dianne Whitfield, our Chief Human Resources Officer, adopted a Rule 10b5-1 trading plan to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provides for the sale of up to 57,925 shares of common stock held by Ms. Whitfield between December 16, 2025 and April 1, 2026.
Dr. Azamian
Adopted 10b5-1 plan – 10-K Feb 23, 2026
William Link
Board of Directors
Adopted 10b5-1 plan – 10-Q Nov 4, 2025
What the company wrote
In September 2025, William Link, a member of our Board of Directors, adopted a Rule 10b5-1 trading plan to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provides for the sale of up to 50,000 shares of common stock held by Dr. Link between December 15, 2025 and December 14, 2026.
Show the other 4 plans

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 9, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Nov 13, 2026 Bobak Azamian
Officer
10,000 $802K
Sep 15, 2026 WILLIAM J LINK
DIRECTOR
12,500 $980K
Sep 4, 2026 Lin Elizabeth Yeu
Member of immediate family of any of the foregoing
3,180 $278K
Sep 4, 2026 Lin Elizabeth Yeu
Officer
10,773 $943K
Sep 4, 2026 Neervannan Seshadri
Officer
4,564 $388K
Sep 4, 2026 BOBAK AZAMIAN
OFFICER
10,000 $906K
Sep 2, 2026 Lin Elizabeth Yeu
Member of immediate family of any of the foregoing
1,590 $127K
Sep 2, 2026 Mottiwala Aziz
Former Officer
8,000 $654K
Sep 2, 2026 Lin Elizabeth Yeu
Officer
5,387 $431K
Sep 2, 2026 BOBAK AZAMIAN
OFFICER
10,000 $801K
Sep 1, 2026 Mottiwala Aziz
Former Officer
77,698 $5.7M
Sep 1, 2026 Lin Elizabeth Yeu
Officer
4,601 $340K
Aug 25, 2026 Mottiwala Aziz
Former Officer
81,332 $5.8M
Aug 19, 2026 Mottiwala Aziz
Former Officer
53,043 $3.8M
Jun 17, 2026 BOBAK AZAMIAN
OFFICER
10,000 $615K
Jun 16, 2026 Farrow Jeffrey S
Officer
14,396 $877K
Jun 15, 2026 Goodrich Katherine
Director
2,954 $183K
Jun 15, 2026 William J Link
Director
12,500 $776K
Mar 20, 2026 Neervannan Seshadri
Officer
2,989 $200K
Mar 19, 2026 Farrow Jeffrey S
Officer
2,186 $146K
Mar 19, 2026 Mottiwala Aziz
Officer
4,440 $297K
Mar 19, 2026 Azamian Bobak R.
Officer, Director
11,964 $802K
Mar 19, 2026 Whitfield Dianne C.
Officer
4,174 $280K
Mar 19, 2026 Wahl Bryan
Officer
4,231 $283K
Mar 19, 2026 Neervannan Seshadri
Officer
4,589 $307K
Mar 19, 2026 Lin Elizabeth Yeu
Officer
390 $26K
Mar 18, 2026 Whitfield Dianne C.
Officer
4,071 $280K
Mar 18, 2026 Wahl Bryan
Officer
4,125 $283K
Mar 18, 2026 Azamian Bobak R.
Officer, Director
11,667 $802K
Mar 18, 2026 Neervannan Seshadri
Officer
3,610 $248K
Mar 18, 2026 Farrow Jeffrey S
Officer
2,133 $147K
Mar 18, 2026 Mottiwala Aziz
Officer
4,330 $298K
Mar 18, 2026 Lin Elizabeth Yeu
Officer
379 $26K
Mar 17, 2026 Azamian Bobak R.
Officer, Director
10,972 $762K
Mar 17, 2026 Neervannan Seshadri
Officer
3,125 $217K
Mar 17, 2026 Farrow Jeffrey S
Officer
2,111 $147K
Mar 17, 2026 Wahl Bryan
Officer
4,084 $283K
Mar 17, 2026 Whitfield Dianne C.
Officer
4,029 $280K
Mar 17, 2026 Lin Elizabeth Yeu
Officer
375 $26K
Mar 17, 2026 Mottiwala Aziz
Officer
4,286 $298K
Mar 16, 2026 WILLIAM J LINK
DIRECTOR
12,500 $860K
Mar 4, 2026 Neervannan Seshadri
Officer
8,366 $641K
Jan 2, 2026 Whitfield Dianne C.
Officer
15,565 $1.3M
Dec 29, 2025 BOBAK AZAMIAN
OFFICER
6,000 $495K
Dec 16, 2025 Lin Elizabeth Yeu
Officer
2,078 $165K
Dec 16, 2025 Whitfield Dianne C.
Officer
7,397 $592K
Dec 15, 2025 William Link
Director
10,446 $846K
Dec 15, 2025 WILLIAM J LINK
DIRECTOR
12,500 $1.0M
Show the other 40 notices

From the Form 144 XML filed with the SEC, since Dec 15, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TARS/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.